ArticleZeitschrift fur Rheumatologie2017

Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis.

C Gissel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.